Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Repeat Dose, Randomized, Two Period Crossover Study to Investigate the Potential Pharmacokinetic Interactions Between Oral GW679769 [casopitant] and Intravenous Cyclophosphamide in Cancer Patients.

Next Previous
Trial Profile

An Open Label, Repeat Dose, Randomized, Two Period Crossover Study to Investigate the Potential Pharmacokinetic Interactions Between Oral GW679769 [casopitant] and Intravenous Cyclophosphamide in Cancer Patients.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Casopitant (Primary) ; Cyclophosphamide
  • Indications Cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GSK

    • Most Recent Events

    • 02 Jul 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 May 2009 Planned end date changed from 1 Oct 2008 to 1 Oct 2009 as reported by ClinicalTrials.gov.
    • 09 Oct 2008 Actual start date changed from August to March 2005, reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top